Veradermics MANE
NYSE MANE
$116.74 -0.51 (-0.43%)
At close: Oct 2, 2026 · 4:00 PM EDT

Veradermics (MANE) Other Accumulated Expenses (2025 - 2026)

Updated

Veradermics (MANE) posted Other Accumulated Expenses of $379,000 for Q2 2026, up 871.8% from the prior quarter.

Analysis

Veradermics (MANE) Other Accumulated Expenses (2025 - 2026) Analysis & Trends

At the end of FY2025, Veradermics' Other Accumulated Expenses came in at $47,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Veradermics 4.88 Bn 4.88 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 379,000.00
Mar 31, 2026 39,000.00
Dec 31, 2025 47,000.00
API Access

Veradermics Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=MANE&period=max&api_key=YOUR_API_KEY